Literature DB >> 2672243

Tissue penetration of the new quinolones in humans.

D N Gerding1, J A Hitt.   

Abstract

Data on the penetration of new quinolones into selected extravascular sites in humans, i.e., blister fluid, sputum, prostatic secretions, cerebrospinal fluid, aqueous humor, bone, prostate tissue, and cells, are reviewed and the data presented in tabular form. Published reports indicate that penetration into all sites, including intracellular sites, is high and exceeds that achievable for other commonly used antimicrobial agents, including penicillins, cephalosporins, and aminoglycosides. Available clinical treatment data support the expected favorable outcome predicted by the high extravascular concentrations achieved with quinolones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672243     DOI: 10.1093/clinids/11.supplement_5.s1046

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  19 in total

1.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.

Authors:  J E Hoppe; C G Simon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

3.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.

Authors:  J E Hoppe; A Dalhoff; D Pfründer
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Fluoroquinolones and surgical prophylaxis.

Authors:  P Dellamonica; E Bernard
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

8.  Determination of pefloxacin concentration in mesenteric lymph nodes by high-performance chromatography.

Authors:  M I Munera; F Cuesta; A Abadia; J Vasquez; M Restrepo
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.